NCT05525715View on ClinicalTrials.gov

A Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

260

Participants

Timeline

Start Date

October 31, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Atopic Dermatitis
Interventions
DRUG

2mg QY201 tablets or 2mg QY201 placebo,BID

2mg QY201 tablets or 2mg QY201 placebo,BID

DRUG

5mg QY201 tablets or 5mg QY201 placebo,BID

5mg QY201 tablets or 5mg QY201 placebo,BID

DRUG

10mg QY201 tablets or 10mg QY201 placebo,QD

10mg QY201 tablets or 10mg QY201 placebo,QD

DRUG

10mg QY201 tablets or 10mg QY201 placebo,BID

10mg QY201 tablets or 10mg QY201 placebo,BID

DRUG

15mg QY201 tablets or 15mg QY201 placebo,BID

15mg QY201 tablets or 15mg QY201 placebo,BID

DRUG

20mg QY201 tablets or 20mg QY201 placebo,BID

20mg QY201 tablets or 20mg QY201 placebo,BID

DRUG

5mg QY201 tablets，BID

5mg QY201 tablets，BID

DRUG

10mg QY201 tablets，BID

10mg QY201 tablets，BID

DRUG

20mg QY201 tablets，BID

20mg QY201 tablets，BID

DRUG

QY201 placebo，BID

QY201placebo，BID

Sponsors
All Listed Sponsors
lead

E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

INDUSTRY

NCT05525715 - A Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis | Biotech Hunter | Biotech Hunter